TY - JOUR
T1 - Using medicare administrative data to conduct postmarketing surveillance of follow-on biologics
T2 - Issues and opportunities
AU - DiMartino, Lisa D.
AU - Curtis, Lesley H.
AU - Williams, Roger L.
AU - Abernethy, Darrell R.
AU - Schulman, Kevin A.
PY - 2008
Y1 - 2008
N2 - By 2010, it is estimated that $10 billion in biologics will have lost patent protection and that generic versions, or "follow-on" biologics, will begin to emerge. The manufacturing processes required to produce biologics are complex, and safety and efficacy profiles may be specific to the manufacturer. Postmarketing surveillance studies may be required to detect rare safety signals. Medicare claims may provide a useful mechanism for postmarketing surveillance of follow-on biologics. The authors briefly describe the regulation of innovator and follow-on biologics, the need for postmarketing surveillance of follow-on biologics, and how Medicare claims data might be used to monitor postapproval safety.
AB - By 2010, it is estimated that $10 billion in biologics will have lost patent protection and that generic versions, or "follow-on" biologics, will begin to emerge. The manufacturing processes required to produce biologics are complex, and safety and efficacy profiles may be specific to the manufacturer. Postmarketing surveillance studies may be required to detect rare safety signals. Medicare claims may provide a useful mechanism for postmarketing surveillance of follow-on biologics. The authors briefly describe the regulation of innovator and follow-on biologics, the need for postmarketing surveillance of follow-on biologics, and how Medicare claims data might be used to monitor postapproval safety.
UR - http://www.scopus.com/inward/record.url?scp=58149163304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149163304&partnerID=8YFLogxK
M3 - Review article
C2 - 19601387
AN - SCOPUS:58149163304
SN - 1064-590X
VL - 63
SP - 891-900+iii
JO - Food and drug law journal
JF - Food and drug law journal
IS - 4
ER -